A Multicenter Open-Label Phase 2a Study of Ibrutinib Monotherapy or in Combination With Either Cytarabine or Azacitidine in Subjects With Acute Myeloid Leukemia.

Trial Profile

A Multicenter Open-Label Phase 2a Study of Ibrutinib Monotherapy or in Combination With Either Cytarabine or Azacitidine in Subjects With Acute Myeloid Leukemia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 May 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Azacitidine; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 18 May 2017 Status changed from recruiting to discontinued.
    • 29 Feb 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2017 as reported by ClinicalTrials.gov record.
    • 29 Feb 2016 Planned number of patients changed from 67 to 101 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top